What's My Wellness Practice Worth?
We value your practice from real normalized earnings up, using a clearly labeled proxy range, so you know where you stand before any buyer does.
Run the estimator →
Home / Who We Serve / Regenerative & Wellness
Emerging Specialty · Sell-Side M&A
Your Wellness Practice Is Built on Trust, Not Trends. We Value the Part That Lasts.
A regenerative practice is not priced on how popular HRT, peptides, or weight-loss medications are this year. It is priced on how well-regulated, compliant, and transferable your service lines actually are.
What's your wellness practice actually worth?
A confidential ballpark in under two minutes, no email required.
Why Regenerative & Wellness Is Different
Why a regenerative & wellness practice is valued differently.
The hard truth is that there is no published, off-the-shelf multiple for a regenerative or longevity practice the way there is for more established specialties. The category is young, the demand for personalized care like hormone therapy is expanding fast, and the deal data has not caught up. Because no dedicated benchmark exists yet, value here is comped against a med-spa-adjacent proxy range and, more importantly, against your own owner economics: your normalized earnings, your margin, and how much of the practice runs without you.
Regulated, Documented Service Lines
Anti-aging and hormone therapy alone do not raise your value. Buyers reward practices where the volatile programs are certified, screened, and monitored correctly. Documented protocols are the difference between a premium and a discount.
Checks and Balances on Volatile Programs
HRT, peptides, and weight-loss medications demand precise management, patient screening, and accurate dosing. The oversight structure you can prove, baseline testing, monthly check-ins, clear contraindication review, is exactly what a quality-of-earnings team underwrites.
Compounding and Supply Resilience
Your value depends on continuity of care that survives regulatory swings. FDA decisions on compounded medications stay fluid, so buyers favor practices tied to reputable, FDA-compliant 503A or 503B pharmacies rather than questionable sourcing.
Transferable, Manager-Run Operations
If you personally generate most of the revenue, you have built a job, not yet a brand. Practices that run on providers, systems, and a loyal patient base hold their value after you step back, and that is what earns the higher end of the range.
| Small, owner-dependent, thin protocols | Lower end of the proxy band | Selective |
| Scaled, documented compliance, provider team | Mid-range of the proxy band | Strong |
| Multi-site, manager-run, resilient sourcing | Top of the proxy band | Competitive |
Estimate only, not a formal valuation, appraisal, or offer. Flagged verticals use a labeled proxy and are directional only. Figures are shown as ranges by design, never a single precise number.
How Value Is Built
No public multiple exists yet. So we comp it honestly.
No dedicated benchmark exists for this category yet, so we comp your practice against a clearly labeled med-spa-adjacent proxy and weight it toward what actually moves your value: regulated service lines, documented compliance, resilient sourcing, and low owner-dependence. Your confidential report normalizes your earnings and shows exactly which moves widen the spread in your favor.
Run my numbers →See Your Number First
Know your number before anyone else does.
A confidential ballpark in under two minutes. No email required to see your range. The estimate is generated on your device. Nothing is stored or sent unless you choose to continue.
Step 1 · Instant ballpark
$3.0M
Estimated enterprise value
$1.4M – $4.7M
Practices like yours trade around 2.6x – 5.3x adjusted earnings.
What raises your number
- Build recurring revenue past 30% of sales
- Reduce owner-performed treatment dependence
- Clean, normalized three-year financials
What lowers your number
- Owner performs the majority of clinical work
- Recurring revenue under 15% of sales
Step 2 · What you receive when you continue
Your custom valuation report. Comparable transactions, your likely buyer pool, and timing analysis.
Your buyer-readiness scorecard. The specific moves that raise your multiple before you go to market.
A confidential 30-minute strategy call with Bill Walker. No obligation, no pressure.
Your information is never shared, and we have never broken a client's confidentiality.
Estimate only. A ballpark from limited inputs plus published industry M&A benchmarks.
Wellness Practice Sellers Ask
Everything that moves your number, in plain English.
Do HRT, Peptides, and GLP-1 Add Value?
Only when they are well-regulated and monitored. We show you which of your service lines a buyer treats as a premium and which they treat as a risk.
See what buyers reward →Compliance, Screening, and Dosing Oversight
The processes you can prove, baseline blood work, contraindication review, monthly check-ins, are part of what we package for buyers as defensible, transferable value.
Test the impact →Compounding Pharmacy and Supply Risk
Fluid FDA decisions on compounded medications can disrupt continuity of care. We help you show buyers a sourcing relationship that holds up under regulatory pressure.
See the sourcing playbook →Confidentiality & Protecting Your Staff
Every process runs under strict confidentiality, with NDAs and staged disclosure, so your team, patients, and competitors learn nothing until you decide they should.
Our confidentiality method →Selling, Merging, or Adding Investment
Whether you want a full exit, a partner's capital, or a merger, we structure the deal around your goals and translate the options into plain English.
See your options →Wellness Track Record · Anonymized
Discretion is the proof.
Single-site HRT Practice
$00.0M
Sell-side advisor
Peptide & Longevity Clinic
$00.0M
Sell-side advisor
Multi-site Wellness Group
$00.0M
Sell-side advisor
GLP-1 Weight-Loss Practice
$00.0M
Sell-side advisor
Tombstone values redacted by design. The published board uses Aesthetic Brokers' verified, client-consented anonymized deals only.
Why This Sale Is Not Like Any Other
What Makes Selling a Regenerative & Wellness Practice Different
Most business brokers, and even some healthcare-adjacent M&A firms, treat a wellness practice the same way they treat a staffing company: revenue in, multiple applied, price out. That approach fails here, because the value of a regenerative or longevity practice is not in the revenue line. It is in the compliance story underneath it. Here is what separates a specialist's read from a generalist's guess.
The Four Things Buyers Actually Pay For
Buyers in this space are not buying a treatment menu. They are buying four specific assets: a documented clinical protocol stack that transfers without the founder, a patient base with recurring contact cadence (memberships, follow-up labs, refill programs), a pharmacy sourcing relationship that survives regulatory swings, and a provider team whose expertise does not walk out the door with you. A practice strong in all four commands a meaningfully wider range than one that is strong in only revenue.
What Silently Depresses Value in This Vertical
Generalist brokers price the top line and miss the discount signals buyers underwrite hard. The three that appear most often in regenerative practices: a compounding pharmacy relationship with a 503A compounder that has no documented FDA-compliance track record; a clinical protocol that lives in the founder's head rather than in a written, auditable SOP; and hormone or peptide dosing that was never connected to baseline labs or a documented monitoring schedule. Each one gives a quality-of-earnings team a reason to widen the risk discount. Fixing them before market is worth far more than any marketing polish.
Why Regulatory Timing Is a Positioning Variable
FDA guidance on compounded semaglutide, tirzepatide, and certain peptide classes has moved more than once in the past two years. A generalist broker cannot tell you how that affects your continuity-of-care narrative with a buyer, because they have not closed a deal in this category. We have. We know which buyers ask about compounding pharmacy certification first, which ones are comfortable with the current regulatory posture, and how to frame your sourcing relationship so it reads as resilient rather than fragile. Timing your process around the regulatory calendar is part of our sell-side work, not an afterthought.
What a Specialist Sees That a Generalist Misses
A generalist broker looks at your revenue, applies a proxy multiple, and presents a number. A sell-side specialist in this category reads the same financials and sees the story underneath: which service lines are high-compliance assets and which are liability risks dressed as revenue, whether your membership program creates genuine contractual recurring revenue or just billing convenience, and whether your clinical team has the credentialing depth a buyer needs to operate without you post-close. That read is what shapes your sale narrative, your buyer targeting, and ultimately the spread between the number a generalist puts on your practice and the number we negotiate on your behalf.
Wellness Practice Sale FAQ
Straight answers, before you commit to anything.
It is valued on your adjusted earnings, or EBITDA, with a multiple on top. Because no dedicated public multiple exists yet for this category, we apply a clearly labeled med-spa-adjacent proxy range and lean on your real economics. Well-regulated, documented service lines and low owner-dependence earn the higher end. Your figure is always a range, never a single number.
No. Offering trendy treatments alone does not increase value. Buyers and investors reward practices where these volatile service lines are properly regulated, screened, and monitored, not merely present on the menu. Without correct procedures, dosing, and oversight, the same programs create liabilities. The premium goes to credible compliance, not to the treatment name itself.
The regenerative and longevity space is young, so the transaction data needed to set a dedicated benchmark does not exist yet. To stay honest, we comp your practice against a clearly labeled med-spa-adjacent proxy range and weight it toward your own earnings, margin, and transferability. We present that as directional only, never as a sourced figure for this vertical.
They affect continuity of care, which buyers watch closely. FDA rulings on compounded medications stay fluid, so investors favor practices tied to reputable, FDA-compliant 503A or 503B pharmacies with clean records. Showing a resilient sourcing relationship and documented protocols protects your value and reassures a buyer that your revenue survives regulatory swings.
No, not unless and until you choose to tell them. We treat confidentiality as part of protecting your value, using confidentiality agreements, staged disclosure, and a vetted buyer process. Premature disclosure can unsettle staff and patients and weaken your position. You decide what is shared, with whom, and when, on your terms.
No. We are sell-side-exclusive, which means we represent the practice owner, never the buyer. Our leadership came from the private-equity buy-side in healthcare, so we know what investors look for and how to position your practice. We bring that experience to your corner so the deal is structured around your goals, not the acquirer’s.
Who you work with
You are advised by Bill Walker, not handed to a junior associate.
Bill Walker founded Aesthetic Brokers after leading mergers and acquisitions for a large private-equity-backed healthcare services organization. Before that he flew for the Marine Corps at the Presidential Helicopter Squadron and commanded a squadron in combat. He knows how an investor values a practice, and how to make sure that value lands with you, not the buyer.
Talk with Bill about your practiceYour wellness practice deserves an uncommon partner.
Start with a confidential, two-minute read on where you stand.